Intravascular Ultrasound in the Drug-Eluting Stent Era
|
|
- Randolph Turner
- 5 years ago
- Views:
Transcription
1 Journal of the American College of Cardiology Vol. 48, No. 3, by the American College of Cardiology Foundation ISSN /06/$32.00 Published by Elsevier Inc. doi: /j.jacc STATE-OF-THE-ART PAPER Intravascular Ultrasound in the Drug-Eluting Stent Era Gary S. Mintz, MD,* Neil J. Weissman, MD New York, New York; and Washington, DC Intravascular ultrasound (IVUS) has become an indispensable part of all drug-eluting stent (DES) studies; findings must be put into context with the IVUS findings in bare metal stents. Unfortunately, there is not yet a complete picture of either the Cypher (Cordis, Miami, Florida) or the Taxus (Boston Scientific, Maple Grove, Minnesota) stent (the two U.S. Food and Drug Administration-approved devices). Intimal hyperplasia volume in DES is reduced to 15% of stent volume, but stent underexpansion continues to be a consistent finding in DES failures (restenosis and thrombosis). The utility of IVUS to assure adequate stent expansion may be more important whenever there are clinical risk factors for DES failure. (J Am Coll Cardiol 2006;48:421 9) 2006 by the American College of Cardiology Foundation In the bare-metal stent (BMS) era serial (post-intervention and follow-up) intravascular ultrasound (IVUS) was crucial to understanding how stents worked and why they failed. Chronic stent recoil was rare, and late lumen loss was almost entirely the result of intimal hyperplasia (IH) (1). To date, IVUS studies of most DES devices have mainly reported and compared percentage IH (%IH) volume, an IVUS measure of efficacy (Fig. 1). Only the IVUS results from the sirolimus-eluting Cypher stent (Cordis, Miami, Florida), the polymeric paclitaxel-eluting Taxus stent (Boston Scientific, Maple Grove, Minnesota), and a nonpolymeric paclitaxel-eluting stent have been studied and reported in detail. This review focuses on the two U.S. Food and Drug Administration (FDA)-approved devices, Cypher and Taxus. INTIMAL HYPERPLASIA In BMS, %IH volume averaged 30% of stent volume; %IH volume was consistently greater in diabetics versus nondiabetics; and in BMS that did not restenose, IH remained stable or regressed slightly after 6 months. Cypher stent. In the RAVEL (Randomized Comparison of a Sirolimus-Eluting Stent with a Standard Stent for Coronary Revascularization) trial, 6-month %IH volume (1 3%) was lower with Cypher stents compared with control subjects (29 20%; p 0.001) (2). In the subset of diabetic patients, Cypher stent %IH volume measured % (vs % in control subjects; p 0.008). Furthermore, Cypher stents compared favorably in diabetics versus nondiabetics in whom %IH volume measured % (3). From the *Cardiovascular Research Foundation, New York, New York; and the Washington Hospital Center, Washington, DC. Dr. Mintz is a consultant to Volcano and receives honoraria from Boston Scientific, the two U.S. manufacturers of IVUS equipment. Dr. Weissman receives grant support and honoria from Boston Scientific. Manuscript received January 12, 2006; revised manuscript received March 15, 2006, accepted April 4, In the SIRIUS (Sirolimus-Eluting Stent in Coronary Lesions) trial, Cypher stents reduced 9-month %IH volumes from 33.4% to 3.1% (p 0.001) (4). There was a tendency for greater neointima suppression in the middle of the stent compared with the edges, the opposite of BMS (5). There was: 1) no difference in IH between lesions with moderate/severe calcium (arc 120 ) versus no/mild calcium; 2) no difference between lesions with positive versus negative pre-intervention vessel remodeling; 3) no correlation between IH and pre-interventional plaque burden (plaque and media [P&M]/external elastic membrane [EEM]); 4) no effect from stent asymmetry; and 5) no difference between overlap versus nonoverlapped segments (6 8). Many weak predictors of BMS restenosis (i.e., pre-intervention positive remodeling and pre-intervention or residual plaque burden) were not predictive after Cypher implantation, because marked IH suppression masked any effect from weaker predictors. In the São Paulo registry, IH within Cypher stents was stable or increased slightly beyond the time points reported in the RAVEL (6 months) and SIRIUS (9 months) trials. The %IH volume in 14 patients treated with the fast-release formulation was 2.3% at 1 year, 9.2% at 2 years, and 9.1% at 4 years; %IH volume in 14 patients treated with the slow-release formulation was 2.2% at 1 year, 3.3% at 2 years, and 5.7% at 4 years (9 11). Taxus stent. In the TAXUS-II trial, 6-month %IH volume measured % in slow-release Taxus stents (vs % in control subjects) and % in moderate-release Taxus stents (vs % in control subjects) (12). The distribution of IH over the length of the stent was neither increased (as in BMS) nor more suppressed in the center (as in Cypher) (13). The findings of the TAXUS-II trial were supported by the TAXUS-IV trial (14); 9-month %IH measured % in slow-release Taxus stents versus % in control subjects (p ). As in the TAXUS-II trial, IH was flat over the length of the stent.
2 422 Mintz and Weissman JACC Vol. 48, No. 3, 2006 IVUS and DES August 1, 2006:421 9 Abbreviations and Acronyms BMS bare-metal stent CSA cross-sectional area EEM external elastic membrane IH intimal hyperplasia ISR in-stent restenosis IVUS intravascular ultrasound LAD left anterior descending LMCA left main coronary artery LSM late stent malapposition MSA minimum stent CSA P&M plaque and media The TAXUS-V trial randomized more complex lesions than the TAXUS-IV trial; %IH volume measured % with Taxus stents versus % with control subjects (p ) (15). The TAXUS-VI trial studied moderate-release Taxus stents in longer lesions; %IH volume measured % versus % in control subjects (p ) (N. J. Weissman, unpublished data, 2005). A subset meta-analysis of 566 patients from the TAXUS- IV, V, and VI trials showed: 1) %IH measured % in overlapping Taxus segments versus % in nonoverlapping segments; and 2) in lesions 26 mm in length, %IH measured % (N. J. Weissman, unpublished data, 2005) In that meta-analysis, %IH in 87 diabetics treated with Taxus stents measured %, i.e., less than the % in 75 diabetics treated with BMS (p ) but no different from the 217 nondiabetics treated with Taxus stents ( %) (16). Two-year TAXUS-II IVUS trial data has been reported in a highly selected group of 32% of Taxus-treated patients who had baseline and 6 month follow-up IVUS. The IH continued to be significantly suppressed compared with BMS. However, IH increased in both the slow-release and moderate-release Taxus stents ( mm 2 to mm 2 [p 0.01] and mm 2 to mm 2 [p 0.009], respectively) (17). EDGE EFFECTS Bare-metal stent implantation caused progressively more EEM cross-sectional area (CSA) decrease (negative remodeling) and progressively less P&M CSA or IH increase at greater distances from the stent edges (1). Cypher stent. In the RAVEL trial, IVUS was only performed at follow-up; therefore, edge effects, requiring serial IVUS imaging, were not addressed. Of 31 Cypher failures in the SIRIUS trial, 27 restenoses were focal and 19 were at the stent edges. Larger reference plaque burdens and larger edge stent CSA/reference minimum lumen CSAs were associated with Cypher edge restenosis, suggesting that incomplete lesion coverage landing the stent edge within a plaque (even a secondary plaque) contributed to edge restenosis (18). Cypher edge restenosis was associated with negative remodeling (EEM decrease) in the first 1 to 3 mm as well as a focal increase in IH just at the edge of the stent (19). Taxus stent. In the TAXUS-II trial, when analyzed mm by mm, there was an increase in EEM CSA, an increase in P&M CSA, and a decrease in lumen CSA within the first 1 mm proximally and within the first 3 mm distally in both slow- and moderate-release Taxus stents. (Edge effects were less obvious when proximal and distal 5-mm long segments were analyzed as a volume.) EEM or P&M were similar comparing proximal and distal edges; however, there was a larger decrease in lumen CSA at the proximal versus the distal edges in both moderate- and slow-release groups (20). In both the TAXUS-IV (14) and TAXUS-VI (N. J. Weissman, unpublished data, 2005) trials, there was also a significant increase in distal lumen CSA at follow-up but no significant change in proximal lumen CSA. Figure 1. This illustration shows the percentage intimal hyperplasia volume from trials of drug-eluting stents. The drug and its carrier vehicle (polymeric or nonpolymeric) and the name of the trial are shown. The time point of the intravascular ultrasound analysis ranged from 4 to 9 months after implantation depending on the trial. (By comparison, after implantation of bare metal stents percentage intimal hyperplasia volume averages 30%.) NO nitric oxide; PC phosphorylcholine.
3 JACC Vol. 48, No. 3, 2006 August 1, 2006:421 9 Mintz and Weissman IVUS and DES 423 VASCULAR RESPONSES In BMS, vascular responses to stent implantation were not limited to the luminal side of the stent or to the proximal and distal reference segments. Abluminal (peri-stent) EEM and P&M both increased (1). Vascular responses with DES were not well studied. In an analysis of 30 patients in the São Paulo registry, peri-stent P&M volume did not change in the first 2 years after Cypher stent implantation but decreased between 2 and 4 years as the plaque became more echoreflective (21). In an analysis of the TAXUS-II trial patients, there was a greater 6-month increase in peri-stent EEM CSA in the moderaterelease group compared with control subjects (but not in the slow-release group compared with control subjects), suggesting a dose-dependent drug effect (13). At 2 years, the 6-month peri-stent increases in EEM and P&M regressed completely in the slow-release group but only incompletely in the moderate-release group (17). LATE STENT MALAPPOSITION (LSM) Late stent malapposition (also called late acquired incomplete stent apposition) occurred in approximately 4% to 5% of BMS, was caused by an increase in EEM that was greater than the increase in peri-stent P&M, but was not associated with adverse events (1). Cypher stent. Because the RAVEL trial did not include post-intervention IVUS, the high rate of Cypher stent malapposition at follow-up (21% vs. 4% in control subjects) could not be separated into acquired versus persistent malapposition (2). In the SIRIUS trial, which had IVUS both at implantation and follow-up, LSM was seen in 8.7% of Cypher stents versus none in control subjects (p 0.05) (Fig. 2) and was associated with an increase in peri-stent EEM CSA. There were no deleterious clinical events in any of these 19 patients at 12 months after stent implantation (22). A longer-term follow-up IVUS study from the RAVEL trial indicated that malapposition discovered at 6 months Figure 2. This patient underwent Cypher stent implantation in a right coronary stenosis; the final angiogram is shown in A. At follow-up (B) there was a focal angiographic aneurysm in the proximal right coronary (arrow). The final (post-implantation) IVUS is shown in C, and the follow-up IVUS is shown in D. Note the late stent malapposition most prominently indicated by the white asterisk. There has been an increase in external elastic membrane cross-sectional area (CSA) from 17.8 mm 2 to 28.9 mm 2 along with an increase in effective lumen CSA (intra-stent lumen CSA plus area of malapposition) from 8.8 mm 2 to 16.8 mm 2. The stent CSA (8.8 mm 2 ) and the peri-stent plaque and media CSA (8.9 mm 2 ) have not changed.
4 424 Mintz and Weissman JACC Vol. 48, No. 3, 2006 IVUS and DES August 1, 2006:421 9 after implantation neither progressed nor regressed over the subsequent 12 months (23). Taxus stent. In the TAXUS-II trial, LSM at 6 months was seen in 8.0% of slow-release and 9.5% of moderate-release Taxus stents (p 0.3 vs. 5.4% in controls). The LSM was caused by an increase in EEM with no increase in peri-stent P&M, and LSM detected at 6 months was not associated with adverse events at 12 months (including no stent thromboses) (24). In a subset of patients studied at 2 years, the incidence of LSM was 0% in the slow-release group (down from 9.3%) and 2.4% in the moderate-release group (down from 9.8%) (17). In the TAXUS-IV trial, LSM was seen in 1.1% of slow-release Taxus stents versus 2.2% of control subjects (14). In the TAXUS-V trial, LSM was seen in 8.7% of slow-release Taxus stents versus 4.1% of control subjects (p 0.3) (15). And in the TAXUS-VI trial, LSM was seen in 16.7% of moderate-release Taxus stents versus 4.3% of control subjects (p 0.018). Finally, in a meta-analysis of the TAXUS-IV, -V, and -VI trials, 9-month LSM was more common in Taxus than in control stents (8.4% vs. 3.5%; p 0.02); this was predominantly driven by non FDA-approved moderate-release Taxus stent use in the TAXUS-VI trial. The LSM was associated with less IH than fully apposed stents. One year later, there were no major adverse cardiac events (including stent thromboses) in any patient with LSM (25). Asan Medical Center experience. Hong et al. (26) evaluated LSM in 557 patients. Late stent malapposition occurred in 13.2% of 538 Cypher versus 8.4% of 167 Taxus stents (p 0.12). The frequency of LSM increased after directional coronary atherectomy before stenting (25%), after primary stenting in acute myocardial infarction (MI) (32%, suggesting that thrombus dissolution may be important in infarct lesions that develop LSM), and in chronic total occlusions (27.5%). Independent predictors of LSM were total stent length, primary stenting in acute MI, and occlusions. In the subgroup of elective stenting after conventional balloon predilation, the only independent predictor of LSM was total stent length. There were no adverse events from implantation to when LSM was detected at 6 months or during the subsequent 12 months. Thus, current experiences do not suggest any definite clinical sequelae from LSM. However, exaggeration of the mechanisms responsible for LSM can cause aneurysm formation. DES THROMBOSIS In BMS, minimum stent area (MSA) and stent expansion (MSA divided by the mean reference lumen CSA) were smaller, calcification was rare, and dissections were common when stent thromboses were compared to nonthrombosed stents (1). Cypher stent. Fifteen patients who developed Cypher stent thrombosis were compared with 45 matched control subjects. The MSA measured mm 2 in Cypher thrombosis (vs mm 2 in control subjects; p 0.001); stent expansion was smaller (65 18% vs %; p 0.001); and a residual edge stenosis (reference minimum lumen CSA 4 mm 2 with a plaque burden 70%) was more common in the thrombosis group (67% vs. 9%; p 0.001). However, there was no difference in the rate of acute or late stent malapposition between the two groups (27). Taxus stent. There have been no IVUS studies of Taxus stent thrombosis. Late thrombosis. In a study of 11 patients (8 with Cypher stents) with late ( 12 months) stent thrombosis, stent expansion (58 25%) was less than in patients without late stent thrombosis (81 17%; p 0.001); and incomplete stent apposition was more common (55% vs. 12%; p ) (28). DES RESTENOSIS When a patient presented with BMS restenosis, IVUS often showed either stent underexpansion or another mechanical complication. The single major IVUS predictor of clinical, angiographic, or IVUS BMS restenosis was the absolute final MSA (1). Cypher stent failure. In a substudy of the SIRIUS trial where adequate patency was defined as a follow-up IVUS minimum lumen CSA 4 mm 2, the post-intervention MSA that best separated adequate from inadequate patency was 5.0 mm 2. The positive predictive value for this cut-off point was 90%, suggesting that Cypher failure in the SIRIUS trials was mostly due to stent underexpansion at the time of implantation (29). In a study of 550 patients with 670 native coronary artery lesions treated with Cypher stents, IVUS cut-offs that best predicted angiographic restenosis were an MSA of 5.5 mm 2 and a stent length of 40 mm. When patients were divided into subgroups, angiographic restenosis rates were 0.4% (MSA 5.5 mm 2 and stent length 40 mm), 2.4% (MSA 5.5 mm 2 and stent length 40 mm), 8.6% (MSA 5.5 mm 2 and stent length 40 mm), and 17.7% (MSA 5.5 mm 2 and stent length 40 mm) (30). In one IVUS study of 33 Cypher failures, an MSA 5.0 mm 2 was observed in 67% (31). In another study of 26 DES failures (21 Cypher stents), MSA measured mm 2 ; 61% had an MSA 5.0 mm 2, and 38% had an MSA 4.0 mm 2 (32). Stent underexpansion is the most common mechanism of Cypher failure. Once IH is suppressed, the impact of stent underexpansion becomes magnified. However, in an analysis of 48 Cypher restenoses, 71% of stents had an MSA 5.0 mm 2 somewhere within the stent, but this occurred at the minimum lumen site in only 46.9%. Therefore, other mechanisms must be considered (33). Cypher stent failure has also been attributed to either strut fractures or gaps between adjacent stent struts (34).
5 JACC Vol. 48, No. 3, 2006 August 1, 2006:421 9 Mintz and Weissman IVUS and DES 425 Figure 3. This long right coronary artery stenosis (A, arrow) was treated with two overlapping Cypher stents (33 mm and 15 mm in length) with the final result in B. At 7-month follow-up there was focal in-stent restenosis (C, arrow). D (final post-implantation intravascular ultrasound [IVUS]) and E (follow-up IVUS) show identical image slices. At the site of focal intimal hyperplasia (E, white asterisk), the minimum lumen CSA (line of white dots) measured 2.0 mm 2, and there was a paucity of stent struts (actually, only 1 stent strut) compared with the same image slice in D. Intimal hyperplasia was very focal and extended for 2 mm proximally and distally. This is an example of focal intra-cypher stent restenosis, probably from strut fracture (struts were apparent at implantation that were not seen at follow-up). Because transducer angulation can affect the number and distribution of the struts seen on a single frame, the diagnosis of strut fracture requires IVUS documentation of stent struts present immediately after the procedure that are no longer seen at follow-up, not merely a paucity of struts at follow-up (Fig. 3). It is not clear whether strut fractures occur with BMS or whether they have been missed, and it is not clear whether Cypher strut fracture is a common or uncommon cause of restenosis. Circumferential stent strut expansion homogeneity can be unpredictable. In 24 Cypher restenoses the minimum lumen site had a larger maximum interstrut angle and fewer stent struts even when normalized for the number of stent cells compared to nonrestenotic sites and stents. By implication, circumferential stent strut distribution affected the dose of sirolimus delivered to the arterial wall and therefore the amount of IH (Fig. 4) (35). There were fewer stent struts in restenotic lesions with adequate stent expansion than in lesions with an MSA 5.0 mm 2 at the minimum lumen site. (33). Taxus stent. There are no data regarding predictors of Taxus stent failure (i.e., the importance of stent underexpansion), stent strut fracture, or effect of nonuniform strut distribution. DES TREATMENT OF BARE-METAL IN-STENT RESTENOSIS Cypher stent. The randomized INDEED (Treatment of IN-stent Restenosis with Drug-Eluting Stent versus Intracoronary beta-radiation) trial reported less recurrent IH after Cypher stent implantation ( mm 2 ) versus intracoronary brachytherapy ( mm 2 )(p 0.048) (S-J. Parks, unpublished data, 2005). Feres et al. (36) reported less recurrent IH after Cypher
6 426 Mintz and Weissman JACC Vol. 48, No. 3, 2006 IVUS and DES August 1, 2006:421 9 Figure 4. Pre-intervention, post-intervention, and follow-up angiograms, respectively, are shown at top; slices a b, and c in the post-intervention and follow-up angiograms correspond to the intravascular ultrasound examples at bottom. In slice b, corresponding to the center of the in-stent restenosis, there is heterogeneous stent strut distribution. Note that the three struts marked with the asterisk are farther apart than the others and that this is associated with more neointimal hyperplasia. (From Takebayashi et al. [35].) implantation ( mm 3 ) in 25 patients treated with Cypher stents versus 25 patients treated with betairradiation (18 14 mm 3 )(p ). Conversely, in the randomized SISR (Sirolimus-Eluting Stent Versus Brachytherapy in Patients With Bare Metal In-Stent Restenosis) trial, mean recurrent IH was similar after Cypher implantation ( mm 3 /mm) and after brachytherapy ( mm 3 /mm) (p 0.3), although proportionately fewer brachytherapy-treated patients were available for analysis, which might have biased the findings (37). Nevertheless, the recurrence rate is higher after Cypher treatment of BMS restenosis than after de novo implantation (38). In 1 study, 9 of 11 patients who failed Cypher stent treatment of BMS restenosis had an MSA 5.0 mm 2 versus 5 of 19 nonrecurrences (p 0.003); 7 recurrent lesions had an MSA 4.0 mm 2 versus 4 nonrecurrences (p 0.02); and a gap between Cypher stents was identified in 3 recurrences versus 1 nonrecurrence (39). Recurrent IH often appeared echolucent, especially in patients with previous brachytherapy failures (40). Taxus stent. In the TAXUS-V ISR, %IH volume measured % in 42 patients treated with Taxus stents. (G. W. Stone, unpublished data, 2006). However, predictors of recurrence have not been reported. CLINICAL USES OF IVUS IN THE DES ERA There are no studies specifically addressing the clinical utility of IVUS in the DES era. In particular, there are no randomized angiographic versus IVUS trials. Assessment and treatment of intermediate stenoses. In the BMS era, a minimal luminal CSA 4.0 mm 2 in a major ( 3 mm) epicardial vessel (excluding the left main coronary
7 JACC Vol. 48, No. 3, 2006 August 1, 2006:421 9 Mintz and Weissman IVUS and DES 427 artery [LMCA]) correlated with ischemia, and a minimal luminal CSA 4.0 mm 2 was associated with a low rate of events with medical therapy (41,42). Moses et al. (43) reported 167 patients with intermediate lesions (angiographic diameter stenosis 50%) from the SIRIUS, TAXUS-IV, and FUTURE I/II (First Use to Underscore Restenosis Reduction With Everolimus) trials. At 1 year, patients treated with DES had similar rates of cardiac death or MI (3.4% vs. 5.4% in BMS; p 0.49) and fewer target vessel revascularizations (3.4% vs. 20.3%; p ), major adverse cardiac events (5.6% vs. 25.4%; p ), and binary angiographic restenoses (1.8% vs. 34.0%; p ); no patient in either group developed stent thrombosis. Stenting of borderline lesions was safe, with a rate of events similar to deferred intervention, questioning the need for IVUS or physiologic assessment of intermediate non-lmca lesions. Conversely, routine DES implantation was not better than judicious decision-making and was presumably more expensive. Intravascular ultrasound can also unmask occult stenoses that may warrant treating with a second or a longer first DES (44). Acute DES expansion, stent apposition, and full lesion coverage. As noted in the preceding, the single number that best predicts an adequate IVUS minimum lumen CSA at follow-up or freedom from angiographic restenosis is a Cypher MSA of 5.0 to 5.5 mm 2. Is this always adequate? First, there are no similar data with Taxus stents. Second, there is still a step-wise relationship between a larger MSA and a lower restenosis rate. Third, SIRIUS trial patients are low risk. Fourth, even this modest cut-off is often not achieved. Interventionalists routinely rely on manufacturersupplied compliance charts to target final stent dimensions based on stent size and inflation pressure. However, a critical IVUS analysis shows that: 1) Cypher and Taxus achieve only 75 10% of predicted minimal stent diameter and 66 17% of predicted MSA; and 2) approximately 25% of Cypher and Taxus implanted into 3.0-mm vessels do not achieve an MSA of 5.0 mm 2 (45). Thus, manufacturer-supplied charts underestimate final stent size. Full stent-vessel wall apposition appeared to be less important than adequate stent expansion. In the study by Hong et al. (26), post-procedure (acute) incomplete stent apposition was observed in 51 DES-treated lesions (7.2%). There were no major adverse cardiac events (including target lesion revascularization), and maximum intra-stent IH CSA at follow-up measured mm 2, similar to stents with complete apposition. In another IVUS study of incompletely apposed Cypher stents, IH at the site of complete malapposition resolution was many times greater than at the site of persistent stent malapposition, and no patient developed angiographic restenosis (46). In the TAXUS-II trial, 8 of 13 acute stent malappositions in the slow-release group resolved, all acute stent malappositions in the moderate-release group resolved, and at 12 months acute stent malappositon was not associated with an increase in adverse clinical events (24). Thus, initial concerns that acute incomplete stent apposition would affect drug delivery to the vessel wall and lead to DES failure appeared to be unfounded, and aggressive adjunct inflations to eliminate acute stent malapposition seemed unwarranted. The restenosis penalty of longer DES is less than after BMS supporting full DES lesion coverage (47). Intravascular ultrasound can be used to identify the proximal and distal reference sites (cross-sections with the largest lumen and least plaque), to measure the distance between these two sites using motorized transducer pullback, and to avoid placing the stent edge into a plaque, a predictor of edge restenosis (18). Selecting the correct DES length the first time should be cost-effective compared with having to implant a second, overlapping stent, and it may be associated with fewer acute complications (48). Specific patient and lesion subsets. Patients at higher risk for Cypher stent thrombosis (49) or restenosis (38) have been described. Whenever these risk factors are present or when consequences of failure would be significant (i.e., unprotected LMCA lesions) (Table 1), stent dimensions should be optimized for vessel size rather than settling for an MSA of 5.0 to 5.5 mm 2. For example, in one published study of 102 patients with LMCA disease treated with Cypher stents where IVUS guidance was used in 86%, MSA measured mm 2, and 1-year target lesion revascularization was necessary in only 2 patients (50). Similarly, in 68 patients with ostial left anterior descending (LAD) stenoses treated with Cypher stents, the MSA measured mm 2, distal LMCA involvement (angiographic diameter stenosis 30% and IVUS plaque burden 40%) was covered with longer stents, only 5.1% developed angiographic restenosis, and none required target lesion revascularization (51). (Conversely, an MSA of 5.0 mm 2 may not be achievable in small vessels, because it corresponds to a 0% residual stenosis in a 2.5-mm vessel and a negative residual stenosis in a 2.5-mm vessel; but it still can be vessel size optimized, and stent expansion [MSA/reference lumen area] in smaller vessels may be the best predictor of an adequate lumen at follow-up [52].) A recent analysis of LAD/diagonal bifurcation lesions treated with the crush technique found the MSA at the side Table 1. Indications for IVUS Imaging During DES Implantation High-risk patient subsets 1) Renal failure (45) 2) Limitations to dual antiplatelet therapy use (45) 3) Diabetes mellitus (34,45) 4) Poor left ventricular function (45) High-risk lesion subsets 1) Left main disease 2) Bifurcations (34,45) 3) Ostial lesions (34) 4) Small vessels (34) 5) Long lesions (34) 6) Treatment of ISR (34) DES drug-eluting stent; ISR in-stent restenosis; IVUS intravascular ultrasound.
8 428 Mintz and Weissman JACC Vol. 48, No. 3, 2006 IVUS and DES August 1, 2006:421 9 branch ostium in 68%, where it measured 4 mm 2 in 44% and 5mm 2 in 82% (53). When treating bifurcation lesions with DES, it may be necessary to pay more attention to the side branch ostium, the most common restenosis location, than was done in the BMS era. Pre-intervention IVUS can determine whether the side branch is involved, whether it is diseased but not stenotic, or whether it is stenotic. Postintervention imaging can determine whether the side branch has been compromised (after provisional stenting) or whether there is adequate stent expansion (after stenting both branches). However, IVUS can not adequately assess the side branch from the main vessel; it is necessary to image the side branch directly. DES failure. Currently, IVUS is the best way to identify and exclude causes of DES failure. All DES failures warrant IVUS study. The optimal treatment for DES failure is not clear. At the least, underexpanded stents (the most common mechanism) should be properly expanded before placing another DES to avoid perpetuating the problem. (It is unclear whether merely expanding an underexpanded DES will be effective, because the drug has already been eluted and additional expansion may cause vessel trauma.) Concerns regarding LSM have been minimized. Late stent malapposition appears to be stable or regress and does not appear to warrant catheter-based treatment. Reprint requests and correspondence: Dr. Gary S. Mintz, Cardiovascular Research Foundation, 611 Pennsylvania Avenue, SE #386, Washington, DC gsm18439@aol.com. REFERENCES 1. Mintz GS. Mechanisms, prevention, and treatment of restenosis. In: Mintz GS. Intracoronary Ultrasound. London: Taylor and Francis, 2005: Serruys PW, Degertekin M, Tanabe K, et al. Intravascular ultrasound findings in the multicenter, randomized, double-blind RAVEL (RAndomized study with the sirolimus-eluting VElocity balloonexpandable stent in the treatment of patients with de novo native coronary artery Lesions) trial. Circulation 2002;106: Abizaid A, Costa MA, Blanchard D, et al. Sirolimus-eluting stents inhibit neointimal hyperplasia in diabetic patients: insights from the RAVEL trial. Eur Heart J 2004;25: Moses JW, Leon MB, Popma JJ, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003;349: Morino Y, Ako J, Sonoda S, et al. Neointimal distribution within sirolimus-eluting stents: a 3-D IVUS interim analysis from the SIRIUS trial (abstr). Circulation 2002;106:II Kaneda H, Koizumi T, Ako J, et al. Impact of intravascular ultrasound lesion characteristics on neointimal hyperplasia following sirolimuseluting stent implantation. Am J Cardiol 2005;96: Kaneda H, Ako J, Honda Y, et al. Impact of asymmetric stent expansion on neointimal hyperplasia following sirolimus-eluting stent implantation. Am J Cardiol 2005;96: Miyazawa A, Shimada Y, Waseda K, et al. Vascular responses after overlapping sirolimus-eluting stent implantation: serial intravascular ultrasound analysis (abstr). Circulation 2005;112:II Sousa JE, Costa MA, Abizaid AC, et al. Sustained suppression of neointimal proliferation by sirolimus-eluting stents: one-year angiographic and intravascular ultrasound follow-up. Circulation 2001; 104: Sousa JE, Costa MA, Sousa AG, et al. Two-year angiographic and intravascular ultrasound follow-up after implantation of sirolimuseluting stents in human coronary arteries. Circulation 2003;107: Sousa JE, Costa MA, Abizaid A, et al. Four-year angiographic and intravascular ultrasound follow-up of patients treated with sirolimuseluting stents. Circulation 2005;111: Colombo A, Drzewiecki J, Banning A, et al. Randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions. Circulation 2003; 108: Tanabe K, Serruys PW, Degertekin M, et al. Chronic arterial responses to polymer-controlled paclitaxel-eluting stents: comparison with bare metal stents by serial intravascular ultrasound analyses: data from the randomized TAXUS-II trial. Circulation 2004;109: Weissman NJ, Koglin J, Cox DA, et al. Polymer-based paclitaxeleluting stents reduce in-stent neointimal tissue proliferation: a serial volumetric intravascular ultrasound analysis from the TAXUS-IV trial. J Am Coll Cardiol 2005;45: Weissman NJ, Ellis SE, Mintz GS, et al. Insights on the effect of polymer-based paclitaxel-eluting stents in long lesions and overlapping stents: final results from the TAXUS-V IVUS substudy (abstr). Circulation 2005;112:II Mintz GS, Weissman NJ, Dawkins K, et al. Taxus neutralizes the impact of diabetes mellitus on in-stent restenosis: a volumetric intravascular ultrasound meta-analysis from the TAXUS IV, V, and VI trials (abstr). J Am Coll Cardiol 2006;47 Suppl B:30B. 17. Aoki J, Colombo A, Dudek D, et al. Peristent remodeling and neointimal suppression two years after polymer-based, paclitaxeleluting stent implantation. Insights from serial intravascular ultrasound analysis in the TAXUS-II study. Circulation 2005;112: Sakurai R, Ako J, Morino Y, et al. Predictors of edge stenosis following sirolimus-eluting stent deployment: a quantitative intravascular ultrasound analysis from the SIRIUS trial. Am J Cardiol 2005;96: Kimura M, Carlier SG, Mintz GS, et al. Stent edge vascular responses after sirolimus-eluting stent implantation: a serial intravascular ultrasound analysis (abstr). Circulation 2005;112:II Serruys PW, Degertekin M, Tanabe K, et al. Vascular responses at proximal and distal edges of paclitaxel-eluting stents: serial intravascular ultrasound analysis from the TAXUS-II trial. Circulation 2004; 109: Aoki J, Abizaid AC, Serruys PW, et al. Evaluation of four-year coronary artery response after sirolimus-eluting stent implantation using serial quantitative intravascular ultrasound and computerassisted grayscale value analysis for plaque composition in event-free patients. J Am Coll Cardiol 2005;46: Ako J, Morino Y, Honda Y, et al. Late incomplete stent apposition after sirolimus-eluting stent implantation: a serial intravascular ultrasound analysis. J Am Coll Cardiol 2005;46: Degertekin M, Serruys PW, Tanabe K, et al. Long-term follow-up of incomplete stent apposition in patients who received sirolimus-eluting stent for de novo coronary lesions: an intravascular ultrasound analysis. Circulation 2003;108: Tanabe K, Serruys PW, Degertekin M, et al. Incomplete stent apposition after implantation of paclitaxel-eluting stents or bare metal stents: insights from the randomized TAXUS-II trial. Circulation 2005;111: Mintz GS, Weissman NJ, Dawkins K, et al. Frequency, predictors, and clinical outcomes of late-acquired incomplete stent apposition in patients treated with Taxus stents: a volumetric intravascular ultrasound meta-analysis from the TAXUS IV, V, and VI trials (abstr). J Am Coll Cardiol 2006;47 Suppl B:26B. 26. Hong M-K, Mintz GS, Lee CW, et al. Late stent malapposition after drug-eluting stent implantation: an intravascular ultrasound analysis with long-term follow-up. Circulation 2006;113: Fujii K, Carlier SG, Mintz GS, et al. Stent underexpansion and residual reference segment stenosis are related to stent thrombosis after sirolimus-eluting stent implantation: an intravascular ultrasound study. J Am Coll Cardiol 2005;45: Cook S, Wenaweser P, Togni M, et al. Intravascular ultrasound in very late DES-stent thrombosis (abstr). J Am Coll Cardiol 2006;47 Suppl B:9B.
9 JACC Vol. 48, No. 3, 2006 August 1, 2006:421 9 Mintz and Weissman IVUS and DES Sonoda S, Morino Y, Ako J, et al. Impact of final stent dimensions on long-term results following sirolimus-eluting stent implantation: serial intravascular ultrasound analysis from the SIRIUS trial. J Am Coll Cardiol 2004;43: Hong MK, Mintz GS, Lee CW, et al. Intravascular ultrasound predictors of angiographic restenosis after sirolimus-eluting stent implantation. Eur Heart J 2006;27: Takebayashi H, Kobayashi Y, Mintz GS, et al. Intravascular ultrasound assessment of lesions with target vessel failure after sirolimuseluting stent implantation. Am J Cardiol 2005;95: Kim S-W, Mintz GS, Escolar E, et al. An intravascular ultrasound analysis of the mechanisms of restenosis comparing drug-eluting stents with brachytherapy. Am J Cardiol 2006;97: Sano K, Mintz GS, Carlier SG, et al. Volumetric intravascular ultrasound assessment of neointimal hyperplasia distribution in sirolimus-eluting stent restenosis. Am J Cardiol In press. 34. Lemos PA, Saia F, Ligthart JM, et al. Coronary restenosis after sirolimus-eluting stent implantation: morphological description and mechanistic analysis from a consecutive series of cases. Circulation 2003;108: Takebayashi H, Mintz GS, Carlier SG, et al. Nonuniform strut distribution correlates with more neointimal hyperplasia after sirolimus-eluting stent implantation. Circulation 2004;110: Feres F, Munoz JS, Abizaid A, et al. Comparison between sirolimuseluting stents and intracoronary catheter-based beta radiation for the treatment of in-stent restenosis. Am J Cardiol 2005;96: Ako J, Honda Y, Sonoda S, et al. Sirolimus-eluting stents vs. intracoronary brachytherapy for the treatment of in-stent restenosis: a serial intravascular ultrasound analysis (abstr). Circulation 2005;112: II Lemos PA, Serruys PW, van Domburg RT, et al. Unrestricted utilization of sirolimus-eluting stents compared with conventional bare stent implantation in the real world : the Rapamycin-Eluting Stent Evaluated at Rotterdam Cardiology Hospital (RESEARCH) registry. Circulation 2004;109: Fujii K, Mintz GS, Kobayashi Y, et al. Contribution of stent underexpansion to recurrence after sirolimus-eluting stent implantation for in-stent restenosis. Circulation 2004;109: Costa MA, Sabate M, Angiolillo DJ, et al. Intravascular ultrasound characterization of the black hole phenomenon after drug-eluting stent implantation. Am J Cardiol 2006;97: Nishioka T, Amanullah AM, Luo H, et al. Clinical validation of intravascular ultrasound imaging for assessment of coronary stenosis severity: comparison with stress myocardial perfusion imaging. J Am Coll Cardiol 1999;33: Abizaid AS, Mintz GS, Mehran R, et al. Long-term follow-up after percutaneous transluminal coronary angioplasty was not performed based on intravascular ultrasound findings: importance of lumen dimensions. Circulation 1999;100: Moses JW, Stone GW, Nikolsky E, et al. Drug-eluting stents in the treatment of intermediate lesions: pooled analysis from four randomized trials. J Am Coll Cardiol 2006;47: Maehara A, Mintz GS, Bui AB, et al. Determinants of angiographically silent stenoses in patients with coronary artery disease. Am J Cardiol 2003;91: di Ribamar Costa J, Mintz GS, Carlier SG, et al. Assessing drugeluting stent expansion: lessons learned from intravascular ultrasound (abstr). J Am Coll Cardiol 2006;47 Suppl B:11B. 46. Kimura M, Mintz GS, Carlier SG, et al. The natural history of acute incomplete sirolimus-eluting stent apposition as assessed by serial intravascular ultrasound. Am J Cardiol In press. 47. Mauri L, O Malley AJ, Popma JJ, et al. Comparison of thrombosis and restenosis risk from stent length of sirolimus-eluting stents versus bare metal stents. Am J Cardiol 2005;95: Stone GW, Ellis SG, Cannon L, et al. Comparison of a polymerbased paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease: a randomized controlled trial. JAMA 2005;294: Iakovou I, Schmidt T, Bonizzoni E, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 2005;293: Park S-J, Kim Y-H, Lee B-K, et al. Sirolimus-eluting stent implantation for unprotected left main coronary artery stenosis: comparison with bare metal stent implantation. J Am Coll Cardiol 2005;45: Seung KB, Kim YH, Park DW, et al. Effectiveness of sirolimuseluting stent implantation for the treatment of ostial left anterior descending artery stenosis with intravascular ultrasound guidance. J Am Coll Cardiol 2005;46: Shimada Y, Honda Y, Hongo Y, et al. Sirolimus-eluting stent implantation in small coronary arteries: predictors of long-term stent patency and neointimal hyperplasia (abstr). Circulation 2005;112: II Costa RA, Mintz GS, Carlier SG, et al. Bifurcation coronary lesions treated with the crush technique: an intravascular ultrasound analysis. J Am Coll Cardiol 2005;46:
Journal of the American College of Cardiology Vol. 46, No. 5, by the American College of Cardiology Foundation ISSN /05/$30.
Journal of the American College of Cardiology Vol. 46, No. 5, 2005 2005 by the American College of Cardiology Foundation ISSN 0735-1097/05/$30.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2005.06.009
More informationDES In-stent Restenosis
DES In-stent Restenosis Roxana Mehran, MD Columbia University Medical Center The Cardiovascular Research Foundation DES Restenosis Mechanisms Predictors Morphological patterns Therapy approach Mechanisms
More informationA Volumetric Intravascular Ultrasound Comparison of Early Drug-Eluting Stent Thrombosis Versus Restenosis
JACC: CARDIOVASCULAR INTERVENTIONS VOL. 2, NO. 5, 2009 2009 BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION ISSN 1936-8798/09/$36.00 PUBLISHED BY ELSEVIER INC. DOI: 10.1016/j.jcin.2009.01.011 A Volumetric
More informationSirolimus-Eluting Stents for Treatment of In-Stent Restenosis
Clinical Investigation Alfonso Medina, MD José Suárez de Lezo, MD Manuel Pan, MD Antonio Delgado, MD José Segura, MD Djordje Pavlovic, MD Francisco Melián, MD Miguel Romero, MD Federico Segura, MD Enrique
More informationPCI for In-Stent Restenosis. CardioVascular Research Foundation
PCI for In-Stent Restenosis ISR of BMS Patterns of In-Stent Restenosis Pattern I : Focal Type IA: Articulation / Gap Type IB: Marginal Type IC: Focal body Type ID: Multifocal Pattern II,III,IV : Diffuse
More informationIVUS Assessment of the Mechanism of In-stent Restenosis? Gary S. Mintz, MD Cardiovascular Research Foundation
IVUS Assessment of the Mechanism of In-stent Restenosis? Gary S. Mintz, MD Cardiovascular Research Foundation SURE Trial: Restenosis in non-stented lesions Average of the two image slices with the smallest
More informationChronic Arterial Responses to Overlapping Paclitaxel-Eluting Stents
JACC: CARDIOVASCULAR INTERVENTIONS VOL. 1, NO. 2, 2008 2008 BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION ISSN 1936-8798/08/$34.00 PUBLISHED BY ELSEVIER INC. DOI: 10.1016/j.jcin.2007.12.005 Chronic
More informationLate and Very Late Drug-Eluting Stent Malapposition Serial 2-Year Quantitative IVUS Analysis
Late and Very Late Drug-Eluting Stent Malapposition Serial 2-Year Quantitative IVUS Analysis Soo-Jin Kang, MD; Gary S. Mintz, MD; Duk-Woo Park, MD; Seung-Whan Lee, MD; Young-Hak Kim, MD; Cheol Whan Lee,
More informationIn-Stent Restenosis. Can we kill it?
In-Stent Restenosis Can we kill it? However, In-stent Restenosis is the most serious problem (2-25%) More than 15, lesions will need treatment because of in-stent restenosis. Varying Prevalence Rates of
More informationPCI for Long Coronary Lesion
PCI for Long Coronary Lesion Shift of a General Idea with the Introduction of DES In the Bare Metal Stent Era Higher Restenosis Rate With Increasing Stent Length and Decreasing Stent Area Restenosis.6.4.2
More informationJournal of the American College of Cardiology Vol. 47, No. 7, by the American College of Cardiology Foundation ISSN /06/$32.
Journal of the American College of Cardiology Vol. 47, No. 7, 2006 2006 by the American College of Cardiology Foundation ISSN 0735-1097/06/$32.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2005.05.102
More informationTechnical considerations in the Treatment of Left Main Lesions Ioannis Iakovou, MD, PhD
Technical considerations in the Treatment of Left Main Lesions Ioannis Iakovou, MD, PhD Onassis Cardiac Surgery Center, Athens, Greece Critical issues in LM PCI Anatomic variability Techniques Variability
More informationInterventional Cardiology
Interventional Cardiology Late Malapposition After Drug-Eluting Implantation An Intravascular Ultrasound Analysis With Long-Term Follow-Up Myeong-Ki Hong, MD, PhD; Gary S. Mintz, MD; Cheol Whan Lee, MD,
More informationPCI for Left Anterior Descending Artery Ostial Stenosis
PCI for Left Anterior Descending Artery Ostial Stenosis Why do you hesitate PCI for LAD ostial stenosis? LAD Ostial Lesion Limitations of PCI High elastic recoil Involvement of the distal left main coronary
More informationDrug Eluting Stents Sometimes Fail ESC Stockholm 29 Set 2010 Stent Thrombosis Alaide Chieffo
Drug Eluting Stents Sometimes Fail ESC Stockholm 29 Set 2010 Stent Thrombosis 11.45-12.07 Alaide Chieffo San Raffaele Scientific Institute, Milan, Italy Historical Perspective 25 20 15 10 5 0 Serruys 1991
More informationHCS Working Group Seminars Macedonia Pallas Hotel, Friday 21 st February Drug-eluting stents Are they all equal?
HCS Working Group Seminars Macedonia Pallas Hotel, Friday 21 st February 2014 Drug-eluting stents Are they all equal? Vassilis Spanos Interventional Cardiologist, As. Director 3 rd Cardiology Clinic Euroclinic
More informationFrequency and Characteristics of Incomplete Stent Apposition During and After Sirolimus-Eluting Stent Implantation
J Cardiol 2007 Aug; 50 2 : 111 118 Frequency and Characteristics of Incomplete Stent Apposition During and After Sirolimus-Eluting Stent Implantation Hiroki Yoshihiro Daisuke Tadashi Yota Naoko Nami Masakazu
More informationIVUS vs FFR Debate: IVUS-Guided PCI
IVUS vs FFR Debate: IVUS-Guided PCI Gary S. Mintz, MD Cardiovascular Research Foundation New York, NY Disclosure Statement of Financial Interest Within the past 12 months, I have had a financial interest/arrangement
More informationLM stenting - Cypher
LM stenting - Cypher Left main stenting with BMS Since 1995 Issues in BMS era AMC Restenosis and TLR (%) 3 27 TLR P=.282 Restenosis P=.71 28 2 1 15 12 Ostium 5 4 Shaft Bifurcation Left main stenting with
More informationEffect of Intravascular Ultrasound- Guided vs. Angiography-Guided Everolimus-Eluting Stent Implantation: the IVUS-XPL Randomized Clinical Trial
Effect of Intravascular Ultrasound- Guided vs. Angiography-Guided Everolimus-Eluting Stent Implantation: the IVUS-XPL Randomized Clinical Trial Myeong-Ki Hong, MD. PhD on behalf of the IVUS-XPL trial investigators
More informationUnprotected LM intervention
Unprotected LM intervention Guideline for COMBAT Seung-Jung Park, MD, PhD Professor of Internal Medicine, Seoul, Korea Current Recommendation for unprotected LMCA Stenosis Class IIb C in ESC guideline
More informationDrug eluting stents (DES) have decreased
JACC: CARDIOVASCULAR IMAGING VOL. 5, NO. 11, 1 1 BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION ISSN 1936-878X/$36. PUBLISHED BY ELSEVIER INC. http://dx.doi.org/1.116/j.jcmg.1.. BRIEF REPORT OCT-Verified
More informationComplex PCI. Your partner in complex PCI: In-stent restenosis (ISR)
Comple PCI Your partner in comple PCI: Your partner in comple PCI: Philips provides a portfolio of specialty coronary diagnostic and therapy devices that enable safe and effective treatment of a wide variety
More informationStent Thrombosis: Patient, Procedural, and Stent Factors. Eugene Mc Fadden Cork, Ireland
Stent Thrombosis: Patient, Procedural, and Stent Factors Eugene Mc Fadden Cork, Ireland Definitions Early 1 yr TAXUS >6months CYPHER Incidence and Timing BMS Registry data
More informationPrimary and mid-term outcome of sirolimus-eluting stent implantation with angiographic guidance alone
Journal of Cardiology (2008) 51, 18 24 Primary and mid-term outcome of sirolimus-eluting stent implantation with angiographic guidance alone Hajime Fujimoto, Susumu Tao, Tomotaka Dohi, Sachiko Ito, Jun
More informationComparison of Sirolimus Versus Paclitaxel Eluting Stents for Treatment of Coronary in-stent Restenosis F. Airoldi, et al. Am J Cardiol (2006)
Comparison of Sirolimus Versus Paclitaxel Eluting Stents for Treatment of Coronary in-stent Restenosis F. Airoldi, et al. Am J Cardiol (2006) 97;1182-7 n&list_uids=16616023 Value of the American College
More informationDeclaration of conflict of interest. Nothing to disclose
Declaration of conflict of interest Nothing to disclose Hong-Seok Lim, Seung-Jea Tahk, Hyoung-Mo Yang, Jin-Woo Kim, Kyoung- Woo Seo, Byoung-Joo Choi, So-Yeon Choi, Myeong-Ho Yoon, Gyo-Seung Hwang, Joon-Han
More informationIntravascular Ultrasound Assessment of Drug-Eluting Stent Coverage of the Coronary Ostium and Effect on Outcomes
Intravascular Ultrasound Assessment of Drug-Eluting Stent Coverage of the Coronary Ostium and Effect on Outcomes Soo-Jin Kang, MD, PhD a, Jung-Min Ahn, MD a, Won-Jang Kim, MD a, Jong-Young Lee, MD a, Duk-Woo
More informationIVUS Analysis. Myeong-Ki. Hong, MD, PhD. Cardiac Center, Asan Medical Center University of Ulsan College of Medicine, Seoul, Korea
IVUS Analysis Myeong-Ki Hong, MD, PhD Cardiac Center, Asan Medical Center University of Ulsan College of Medicine, Seoul, Korea Intimal disease (plaque) is dense and will appear white Media is made of
More informationStent Malapposition After Sirolimus-Eluting and Bare-Metal Stent Implantation in Patients with ST-Segment Elevation Myocardial Infarction
JACC: CARDIOVASCULAR INTERVENTIONS VOL. 1, NO. 2, 2008 2008 BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION ISSN 1936-8798/08/$34.00 PUBLISHED BY ELSEVIER INC. DOI: 10.1016/j.jcin.2008.02.003 Stent Malapposition
More informationUpgrade of Recommendation
Challenges in LM PCI Decision-making process for stenting Young-Hak Kim, MD, PhD, Heart Institute, University of Ulsan College of Medicine Asan Medical Center, Seoul, Korea Upgrade of Recommendation for
More informationDRUG ELUTING STENTS. Cypher Versus Taxus: Are There Differences? Introduction. Methods SIGMUND SILBER, M.D., F.E.S.C., F.A.C.C.
DRUG ELUTING STENTS Cypher Versus Taxus: Are There Differences? SIGMUND SILBER, M.D., F.E.S.C., F.A.C.C. From the Cardiology Practice and Hospital, Munich, Germany Today, drug-eluting stents (DES) are
More informationTLR des Stents Actifs
TLR des Stents Actifs No Conflict of Interest Target Lesion Revascularization DES vs BMS Stettler C et al. Lancet 2007;370:937-48 N=18,023 58% 70% SES vs BMS: HR=0.30 (0.24-0.37), p
More informationWhat Coronary Specialists Teach The Vascular Community About Vessel Prep? Tony Das, MD Texas Health, Dallas Dallas, Texas
What Coronary Specialists Teach The Vascular Community About Vessel Prep? Tony Das, MD Texas Health, Dallas Dallas, Texas Stent Era Lessons on Vessel Preparation Under expanded stent consequences Abrupt
More informationRationale for Percutaneous Revascularization ESC 2011
Rationale for Percutaneous Revascularization Marie Claude Morice, Massy FR MD, FESC, FACC ESC 2011 Paris Villepinte - 27-31 August, 2011 Massy, France Potential conflicts of interest I have the following
More informationLong-Term Clinical Outcomes With Sirolimus-Eluting Coronary Stents
Journal of the American College of Cardiology Vol. 50, No. 14, 2007 2007 by the American College of Cardiology Foundation ISSN 0735-1097/07/$32.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2007.06.029
More informationKomplexe Koronarintervention heute: Von Syntax zu bioresorbierbaren Stents
Komplexe Koronarintervention heute: Von Syntax zu bioresorbierbaren Stents Prof. Dr. med. Julinda Mehilli Medizinische Klinik und Poliklinik I Klinikum der Universität München Campus Großhadern Key Factors
More informationLesions at coronary bifurcations represent a challenging
Randomized Study to Evaluate Sirolimus-Eluting Stents Implanted at Coronary Bifurcation Lesions Antonio Colombo, MD; Jeffrey W. Moses, MD; Marie Claude Morice, MD; Josef Ludwig, MD; David R. Holmes, Jr,
More informationVery late thrombosis of sirolimus-eluting stent due to late malapposition: Serial observations with optical coherence tomography
Journal of Cardiology (2008) 52, 290 295 CASE REPORT Very late thrombosis of sirolimus-eluting stent due to late malapposition: Serial observations with optical coherence tomography Takahiro Sawada (MD),
More informationDES in Diabetic Patients
DES in Diabetic Patients Charles Chan, M.D., FACC Gleneagles Hospital Singapore TCT ASIA PACIFIC 2007 Why do diabetics have worse outcome after PCI? More extensive atherosclerosis and diffuse disease Increase
More informationAlthough a feasible therapeutic alternative to bypass
Comprehensive Intravascular Ultrasound Assessment of Stent Area and Its Impact on Restenosis and Adverse Cardiac Events in 403 Patients With Unprotected Left Main Disease Soo-Jin Kang, MD, PhD; Jung-Min
More informationGoal: Optimal Stent Deployment
Ground breaking, Life changing Goal: Optimal Stent Deployment Ground breaking, Life changing Cordis Corporation has no independent knowledge concerning the information contained in these presentations.
More informationDrug eluting stents. Where are we now and what can we expect in 2003? Tony Gershlick Leicester
Drug eluting stents Where are we now and what can we expect in 2003? Tony Gershlick Leicester Trials Real World What we need i. Prevent restenosis cost effective Either : - Treat all at equivalent cost
More informationIncidence and predictors of drug-eluting stent fractures in long coronary disease
International Journal of Cardiology 133 (2009) 354 358 www.elsevier.com/locate/ijcard Incidence and predictors of drug-eluting stent fractures in long coronary disease Hyun-Sook Kim a, Young-Hak Kim b,
More informationFFR and IVUS Guided DES Implantation in Long Diffuse Lesions
FFR and IVUS Guided DES Implantation in Long Diffuse Lesions Can We Reach Optimal DES Expansion With Conventional Stent Delivery System in Long Diffuse Lesion? Seung-Jea Tahk, MD., PhD. Ajou University
More informationIntegrated Use of IVUS and FFR for LM Stenting
Integrated Use of IVUS and FFR for LM Stenting Gary S. Mintz, MD Cardiovascular Research Foundation Four studies have highlighted the inaccuracy of angiography in the assessment of LMCA disease Fisher
More informationC h a p t e r 5 8 Drug Eluting Stents : A New Revolution in the Treatment of Coronary Artery Disease
C h a p t e r 5 8 Drug Eluting Stents : A New Revolution in the Treatment of Coronary Artery Disease Gunasekaran Sengottuvel, MD Marie-Claude Morice, MD Institut Cardiovasculaire Paris Sud, Institut Hospitalier
More informationClinical Investigations
Clinical Investigations Clinical Outcomes for Single Stent and Multiple Stents in Contemporary Practice Qiao Shu Bin, MD; Liu Sheng Wen, MD; Xu Bo, BS; Chen Jue, MD; Liu Hai Bo, MD; Yang Yue Jin, MD; Chen
More informationPaclitaxel-Eluting Coronary Stents in Patients With Diabetes Mellitus
Journal of the American College of Cardiology Vol. 51, No. 7, 2008 2008 by the American College of Cardiology Foundation ISSN 0735-1097/08/$34.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2007.10.035
More informationIn-stent Restenosis Diagnostic and Therapeutic Challenges. Kostis Raisakis General Hospital of Athens «G. Gennimatas»
In-stent Restenosis Diagnostic and Therapeutic Challenges Kostis Raisakis General Hospital of Athens «G. Gennimatas» Introduction With POBA, rates of acute and chronic vessel occlusion at 30% to 60%, secondary
More informationCoronary artery disease (CAD) is the REVIEW PROJECTED HEALTH AND ECONOMIC BENEFITS OF THE USE OF SIROLIMUS-ELUTING CORONARY STENTS
PROJECTED HEALTH AND ECONOMIC BENEFITS OF THE USE OF SIROLIMUS-ELUTING CORONARY STENTS Rodolphe Ruffy, MD, FACC,* and Raymond J. Kaden, MBA, CPA ABSTRACT Despite remarkable technological progress in interventional
More informationDESolve NX Trial Clinical and Imaging Results
DESolve NX Trial Clinical and Imaging Results Alexandre Abizaid, MD, PhD, Instituto Dante Pazzanese, Sao Paulo, Brazil On behalf of the DESolve Nx Trial Investigators Please refer to the TCT2014 App or
More informationDrug eluting stents From revolution to evolution. Current limitations
Drug eluting stents From revolution to evolution Current limitations Eric Eeckhout Centre Hospitalier Universitaire Vaudois Lausanne - Switzerland eric.eeckhout@chuv.ch Overview Historical perspective
More informationIntravascular Ultrasound Predictors for Edge Restenosis After Newer Generation Drug-Eluting Stent Implantation
Intravascular Ultrasound Predictors for Edge After Newer Generation Drug-Eluting Stent Implantation Soo-Jin Kang, MD, PhD a, Young-Rak Cho, MD a, Gyung-Min Park, MD a, Jung-Min Ahn, MD a, Won-Jang Kim,
More information2010 Korean Society of Cardiology Spring Scientific Session Korea Japan Joint Symposium. Seoul National University Hospital Cardiovascular Center
2010 Korean Society of Cardiology Spring Scientific Session Korea Japan Joint Symposium Does Lt Late Cth Catch up Exist Eiti in DES? : Quantitative Coronary Angiography Analysis Kyung Woo Park, MD Cardiovascular
More informationPerspective of LM stenting with Current registry and Randomized Clinical Data
Asian Pacific TCT Perspective of LM stenting with Current registry and Randomized Clinical Data Patrick W. Serruys MD PhD Yoshinobu Onuma MD Seung-Jung Park MD, PhD 14:48-15:00, 2009 Symposium Arena, Level
More informationBéla MERKELY MD, PhD, DSc, FESC. Stent thrombosis: patophysiology, predisposing factors, definition, classification, prevention and treatment
Semmelweis University Heart Center Budapest, Hungary Béla MERKELY MD, PhD, DSc, FESC Stent thrombosis: patophysiology, predisposing factors, definition, classification, prevention and treatment 10th Interventional
More informationImportant LM bifurcation studies update
8 th European Bifurcation Club 12-13 October 2012 - Barcelona Important LM bifurcation studies update I Sheiban E-mail: isheiban@yahoo.com Unprotected LM Percutaneous Revascularization What is important
More informationAngiographic long-term results after implantation of the paclitaxel-eluting coronary stent coroflex please : Data under real-world conditions
244 U. Gerk, B. Leithäuser, U. Schäfer, F. Jung, J.-W. Park Applied Cardiopulmonary Pathophysiology 14: 244-249, 2010 Angiographic long-term results after implantation of the paclitaxel-eluting coronary
More informationOriginal paper. Introduction. Material and methods. Aim
Original paper Relation between coronary plaque calcium deposits as described by computed tomography coronary angiography and acute results of stent deployment as assessed by intravascular ultrasound Jerzy
More informationCalcium Removal and Plaque Modification in the Era of DEB and Contemporary Stenting for Femoro- Popliteal Disease
Calcium Removal and Plaque Modification in the Era of DEB and Contemporary Stenting for Femoro- Popliteal Disease Thomas M. Shimshak, MD Heart and Vascular Center Florida Hospital Heartland Medical Center
More informationSTENTYS for Le, Main Sten2ng. Carlo Briguori, MD, PhD Clinica Mediterranea Naples, Italy
STENTYS for Le, Main Sten2ng Carlo Briguori, MD, PhD Clinica Mediterranea Naples, Italy Disclosure Statement of Financial Interest I, Carlo Briguori DO NOT have a financial interest/ arrangement or affilia2on
More informationKurdistan Technique for the Treatment of Unprotected Trifurcation Left Main Stem Coronary Artery Lesion: Case Report
World Journal of Cardiovascular Diseases, 2014, 4, 483-491 Published Online August 2014 in SciRes. http://www.scirp.org/journal/wjcd http://dx.doi.org/10.4236/wjcd.2014.49058 Kurdistan Technique for the
More informationΑγγειοπλαστική σε Eπαναστενωτικές Bλάβες
Αγγειοπλαστική σε Eπαναστενωτικές Bλάβες Βάιος Π. Τζίφος Δ/ντής Γ Καρδιολογικής Κλινικής - Επεμβατικής Καρδιολογίας. Ερρίκος Ντυνάν HC The Mehran s Classification for BMS-ISR Prognostic Value Pattern (1)
More informationJournal of the American College of Cardiology Vol. 48, No. 2, by the American College of Cardiology Foundation ISSN /06/$32.
Journal of the American College of Cardiology Vol. 48, No. 2, 2006 2006 by the American College of Cardiology Foundation ISSN 0735-1097/06/$32.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2006.03.039
More informationKey Words Angioplasty Coronary artery disease Revascularization Stent drug eluting stent
J Cardiol 26 Dec; 48 6 : 325 331 3 mm : Initial and Mid-Term Effects of 3 mm Long Sirolimus-Eluting Stents in Patients With Diffuse Long Coronary Lesions: Comparison With Bare Metal Stents Abstract Yosuke
More informationOptimization of Stent Deployment by Intravascular Ultrasound
review korean j intern med 212;27:3-38 ORIGINAL ARTICLE pissn 1226-333 eissn 25-6648 Optimization of Stent Deployment by Intravascular Ultrasound Hyuck-Jun Yoon and Seung-Ho Hur Department of Internal
More informationnon-diabetic) compared to a 42% rate in the diabetic population assigned to bare metal stents (P=0.001). After 12 months, there was one non-q-wave MI
J Am Coll Cardiol (2004);43:1118-21 First human experience with the 17-beta-estradiol-eluting stent: the Estrogen And Stents To Eliminate Restenosis (EASTER) trial A. Abizaid, et al. Institute Dante Pazzanese
More informationDEB experience in Gachon Universtiy Gil Hospital (in ISR) Soon Yong Suh MD., PhD. Heart Center Gachon University Gil Hospital Seoul, Korea.
DEB experience in Gachon Universtiy Gil Hospital (in ISR) Soon Yong Suh MD., PhD. Heart Center Gachon University Gil Hospital Seoul, Korea. In-stent restenosis (ISR) Remains important issue even in the
More informationJournal of the American College of Cardiology Vol. 48, No. 2, by the American College of Cardiology Foundation ISSN /06/$32.
Journal of the American College of Cardiology Vol. 48, No. 2, 2006 2006 by the American College of Cardiology Foundation ISSN 0735-1097/06/$32.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2006.01.080
More informationStent Thrombosis in Bifurcation Stenting
Summit TCT Asia Pacific 2009 Stent Thrombosis in Bifurcation Stenting Associate Professor Tan Huay Cheem MBBS, M Med(Int Med), MRCP, FRCP(UK), FAMS, FACC, FSCAI Director, National University Heart Centre,
More informationThe BIO revolution: bioadsorbable stents. Federico Conrotto Cardiologia 2 Città della Salute e della Scienza di Torino
The BIO revolution: bioadsorbable stents Federico Conrotto Cardiologia 2 Città della Salute e della Scienza di Torino BVS stent (Abbot Vascular) Strut Material: Poly-L-Lactic acid Coating Material: Poly-D,L-lactide
More informationCase Report Coronary Artery Perforation and Regrowth of a Side Branch Occluded by a Polytetrafluoroethylene-Covered Stent Implantation
International Scholarly Research Network Volume 2011, Article ID 212851, 4 pages doi:10.5402/2011/212851 Case Report Coronary Artery Perforation and Regrowth of a Side Branch Occluded by a Polytetrafluoroethylene-Covered
More informationProtection of side branch is essential in treating bifurcation lesions: overview
Angioplasty Summit TCT Asia Pacific Seoul, April 26-28, 2006 Protection of side branch is essential in treating bifurcation lesions: overview Alfredo R Galassi, MD, FACC, FSCAI, FESC Head of the Catetherization
More informationAngiographic and Intravascular Ultrasound Predictors of In-Stent Restenosis
1630 JACC Vol. 32, No. 6 Angiographic and Intravascular Ultrasound Predictors of In-Stent Restenosis SHUNJI KASAOKA, MD, JONATHAN M. TOBIS, MD, FACC, TATSURO AKIYAMA, MD,* BERNHARD REIMERS, MD,* CARLO
More informationPercutaneous Intervention of Unprotected Left Main Disease
Percutaneous Intervention of Unprotected Left Main Disease Technical feasibility and Clinical outcomes Seung-Jung Park, MD, PhD, FACC Professor of Internal Medicine Asan Medical Center, Seoul, Korea Unprotected
More informationOCT in the Evaluation of Vascular Healing Following DES Implantation: Will It Be a Helpful Tool to Reduce Stent Thrombosis?
OCT in the Evaluation of Vascular Healing Following DES Implantation: Will It Be a Helpful Tool to Reduce Stent Thrombosis? Juan F. Granada, MD Medical Director, Skirball Center for Cardiovascular Research
More informationJournal of the American College of Cardiology Vol. 47, No. 8, by the American College of Cardiology Foundation ISSN /06/$32.
Journal of the American College of Cardiology Vol. 47, No. 8, 2006 2006 by the American College of Cardiology Foundation ISSN 0735-1097/06/$32.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2005.11.066
More informationISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions
Julinda Mehilli, MD Deutsches Herzzentrum Technische Universität Munich Germany ISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions Background Left main
More informationDOI: /CIRCINTERVENTIONS
Comparison of Zotarolimus-Eluting Stents With Sirolimus-Eluting and Paclitaxel-Eluting Stents Intimal Hyperplasia and Vascular Changes Assessed by Volumetric Intravascular Ultrasound Analysis Soo-Jin Kang,
More informationTO ASSESS THE ADEQUACY OF CORONARY STENTS DEPLOYMENT (APPOSITION)WITH INTRAVASCULAR ULTRASOUND IN COMPARISON WITH CORONARY ANGIOGRAPHY
ORIGINAL ARTICLE TO ASSESS THE ADEQUACY OF CORONARY STENTS DEPLOYMENT (APPOSITION)WITH INTRAVASCULAR ULTRASOUND IN COMPARISON WITH CORONARY ANGIOGRAPHY 1 2 3 4 Iftikhar Ahmad Khan, Jabar Ali, Abdul Wali
More informationDrug Eluting Stents: Bifurcation and Left Main Approach
TCT Asia 2006 Drug Eluting Stents: Bifurcation and Left Main Approach Eberhard Grube MD FACC, FSCAI Heart Center,, Germany Stanford University, School of Medicine, CA, USA DES in High Risk Lesions TAXUS
More informationAnalysis of neointimal coverage after silolimus-eluting stent implantation using optical coherence tomography.
Analysis of neointimal coverage after silolimus-eluting stent implantation using optical coherence tomography. Division of Cardiology, Department of Internal Medicine, Fasculty of Medicine, Kinki University,
More informationMechanisms and Predictors of Carotid Artery Stent Restenosis A Serial Intravascular Ultrasound Study
Journal of the American College of Cardiology Vol. 47, No. 12, 2006 2006 by the American College of Cardiology Foundation ISSN 0735-1097/06/$32.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2006.01.076
More informationGary S. Mintz,, MD. IVUS Observations in Acute (vs Chronic) Coronary Artery Disease: Structure vs Function
Gary S. Mintz,, MD IVUS Observations in Acute (vs Chronic) Coronary Artery Disease: Structure vs Function Important IVUS Observations: Remodeling Originally used (first by Glagov) ) to explain atherosclerosis
More informationSide Branch Occlusion
Side Branch Occlusion Mechanism, Outcome, and How to avoid it From COBIS II Registry Hyeon-Cheol Gwon Cardiac&Vascular Center, Samsung Medical Center Sungkyunkwan University School of Medicine SB occlusion
More informationRESTENOSIS Facing up to the problem
RESTENOSIS Facing up to the problem Petr Kala University Hospital Brno Czech Republic ESC 2011, Paris Disclosure Scientific Advisory Boards or Education presentations fee Abbott, Boston Scientific, Cordis
More informationOriginal Research Article. S. Praveen 1, Baiju R. 1 *, V. V. Radhakrishnan 1, Sarosh Kumar K. K. 2
International Journal of Research in Medical Sciences Praveen S et al. Int J Res Med Sci. 2018 Feb;6(2):448-454 www.msjonline.org pissn 2320-6071 eissn 2320-6012 Original Research Article DOI: http://dx.doi.org/10.18203/2320-6012.ijrms20180029
More informationOptical coherence tomography evaluation of zotarolimus-eluting stents at 9-month follow-up: comparison with sirolimus-eluting stents
Optical coherence tomography evaluation of zotarolimus-eluting stents at 9-month follow-up: comparison with sirolimus-eluting stents J-S Kim, 1 I-K Jang, 2 J-S Kim, 1 T H Kim, 1 M Takano, 3 T Kume, 4 N
More informationEffectiveness of Drug-Eluting Stents in Patients With Bare-Metal In-Stent Restenosis
Journal of the American College of Cardiology Vol. 49, No. 5, 2007 2007 by the American College of Cardiology Foundation ISSN 0735-1097/07/$32.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2006.10.049
More informationThe Site of Plaque Rupture in Native Coronary Arteries
Journal of the American College of Cardiology Vol. 46, No. 2, 2005 2005 by the American College of Cardiology Foundation ISSN 0735-1097/05/$30.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2005.03.067
More informationOne-Year Outcomes After Everolimus-Eluting Stents Implantation in Ostial Lesions of Left Anterior Descending Coronary Arteries
Elmer Press Original Article One-Year Outcomes After Everolimus-Eluting Stents Implantation in Ostial Lesions of Left Anterior Descending Coronary Arteries Zahra Golmohamadi a, c, Sepideh Sokhanvar b,
More informationMULTIVESSEL PCI. IN DRUG-ELUTING STENT RESTENOSIS DUE TO STENT FRACTURE, TREATED WITH REPEAT DES IMPLANTATION
MULTIVESSEL PCI. IN DRUG-ELUTING STENT RESTENOSIS DUE TO STENT FRACTURE, TREATED WITH REPEAT DES IMPLANTATION C. Graidis, D. Dimitriadis, A. Ntatsios, V. Karasavvides Euromedica Kyanous Stavros, Thessaloniki.
More informationContemporary therapy of bifurcation lesions
Contemporary therapy of bifurcation lesions Dr Angela Hoye MB ChB PhD MRCP Interventional Cardiologist Kingston-upon-Hull, UK Hull The challenge of bifurcations Risk of peri-procedural infarction Relatively
More informationDespite its benefit over balloon angioplasty in patients
Coronary Heart Disease Quantitative Assessment of Angiographic Restenosis After Sirolimus-Eluting Stent Implantation in Native Coronary Arteries Jeffrey J. Popma, MD; Martin B. Leon, MD; Jeffrey W. Moses,
More informationStent thrombosis (ST) has complicated coronary artery
Interventional Cardiology Incomplete Stent Apposition and Very Late Stent Thrombosis After Drug-Eluting Stent Implantation Stéphane Cook, MD; Peter Wenaweser, MD; Mario Togni, MD; Michael Billinger, MD;
More informationThe publication in January 2001 of the first-in-man
MINI-REVIEW: EXPERT OPINIONS Drug-Eluting Stents Cost Versus Clinical Benefit Pedro A. Lemos, MD; Patrick W. Serruys, MD, PhD; J. Eduardo Sousa, MD, PhD The publication in January 2001 of the first-in-man
More informationStent Thrombosis in Randomized Clinical Trials of Drug-Eluting Stents
T h e n e w e ng l a nd j o u r na l o f m e dic i n e original article Thrombosis in Randomized Clinical Trials of Drug-Eluting s Laura Mauri, M.D., Wen-hua Hsieh, Ph.D., Joseph M. Massaro, Ph.D., Kalon
More informationResults of the Washington Radiation for In-Stent Restenosis Trial for Long Lesions (Long WRIST) Studies
Intracoronary Radiation Therapy Improves the Clinical and Angiographic Outcomes of Diffuse In-Stent Restenotic Lesions Results of the Washington Radiation for In-Stent Restenosis Trial for Long Lesions
More information